Tags

Type your tag names separated by a space and hit enter

Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Med Pediatr Oncol. 1996 Jan; 26(1):10-9.MP

Abstract

A total of 125 children, who were diagnosed as having high-risk acute lymphoblastic leukemia (ALL), were treated with two consecutive protocols designated as AL851 (1985-1988) and ALHR88 (1988-1990). All patients received induction therapy consisting of vincristine (VCR), prednisolone (PSL), daunorubicin (DNR), and I-asparaginase (I-Asp). In the ALHR88 protocol, the patients whose blasts in the bone marrow (BM) were > or = 25% on day 14 of induction therapy and who were classified into T-cell type received additional cytosine arabinoside (AraC). After consolidation with intermediate-dose methotrexate (MTX), reinduction therapy including VCR, dexamethasone, and adriamycin followed by high-dose AraC was done for all patients. Intrathecal MTX and 24Gy of cranial irradiation were used to prevent central nervous system leukemia. A maintenance therapy consisting of 6-mercaptopurine, cyclophosphamide, MTX, DNR, VCR, and AraC was administered for 3 years after achieving a complete remission (CR). CR was achieved in 51/55 (92.7%) for AL851 and 68/70 (97.1%) for ALHR88. The 5-year event-free survival rates were 49.1 +/- 6.7% in AL851 and 62.5 +/- 6.1% in ALHR88. The factors related to a poor prognosis were a high initial leukocyte count of greater than 50 x 10(9)/L (P < 0.001), an L2 morphology of leukemic cells by FAB classification (P = 0.009), the chromosomal abnormality (P = 0.004) and high residual leukemic cells in BM (> or = 25%) on day 14 of induction therapy (P < 0.001). Taking these factors into consideration, more intensive protocols were started in 1990 for the patients with high-risk ALL.

Authors+Show Affiliations

Department of Pediatrics, Kyushu University, Fukuoka, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

7494507

Citation

Matsuzaki, A, et al. "Treatment of High-risk Acute Lymphoblastic Leukemia in Children Using the AL851 and ALHR88 Protocols: a Report From the Kyushu-Yamaguchi Children's Cancer Study Group in Japan." Medical and Pediatric Oncology, vol. 26, no. 1, 1996, pp. 10-9.
Matsuzaki A, Ishii E, Okamura J, et al. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan. Med Pediatr Oncol. 1996;26(1):10-9.
Matsuzaki, A., Ishii, E., Okamura, J., Eguchi, H., Yoshida, N., Yanai, F., Inoue, T., Miyake, K., Ishihara, T., & Tsuboi, C. (1996). Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan. Medical and Pediatric Oncology, 26(1), 10-9.
Matsuzaki A, et al. Treatment of High-risk Acute Lymphoblastic Leukemia in Children Using the AL851 and ALHR88 Protocols: a Report From the Kyushu-Yamaguchi Children's Cancer Study Group in Japan. Med Pediatr Oncol. 1996;26(1):10-9. PubMed PMID: 7494507.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan. A1 - Matsuzaki,A, AU - Ishii,E, AU - Okamura,J, AU - Eguchi,H, AU - Yoshida,N, AU - Yanai,F, AU - Inoue,T, AU - Miyake,K, AU - Ishihara,T, AU - Tsuboi,C, PY - 1996/1/1/pubmed PY - 2000/6/20/medline PY - 1996/1/1/entrez SP - 10 EP - 9 JF - Medical and pediatric oncology JO - Med Pediatr Oncol VL - 26 IS - 1 N2 - A total of 125 children, who were diagnosed as having high-risk acute lymphoblastic leukemia (ALL), were treated with two consecutive protocols designated as AL851 (1985-1988) and ALHR88 (1988-1990). All patients received induction therapy consisting of vincristine (VCR), prednisolone (PSL), daunorubicin (DNR), and I-asparaginase (I-Asp). In the ALHR88 protocol, the patients whose blasts in the bone marrow (BM) were > or = 25% on day 14 of induction therapy and who were classified into T-cell type received additional cytosine arabinoside (AraC). After consolidation with intermediate-dose methotrexate (MTX), reinduction therapy including VCR, dexamethasone, and adriamycin followed by high-dose AraC was done for all patients. Intrathecal MTX and 24Gy of cranial irradiation were used to prevent central nervous system leukemia. A maintenance therapy consisting of 6-mercaptopurine, cyclophosphamide, MTX, DNR, VCR, and AraC was administered for 3 years after achieving a complete remission (CR). CR was achieved in 51/55 (92.7%) for AL851 and 68/70 (97.1%) for ALHR88. The 5-year event-free survival rates were 49.1 +/- 6.7% in AL851 and 62.5 +/- 6.1% in ALHR88. The factors related to a poor prognosis were a high initial leukocyte count of greater than 50 x 10(9)/L (P < 0.001), an L2 morphology of leukemic cells by FAB classification (P = 0.009), the chromosomal abnormality (P = 0.004) and high residual leukemic cells in BM (> or = 25%) on day 14 of induction therapy (P < 0.001). Taking these factors into consideration, more intensive protocols were started in 1990 for the patients with high-risk ALL. SN - 0098-1532 UR - https://www.unboundmedicine.com/medline/citation/7494507/Treatment_of_high_risk_acute_lymphoblastic_leukemia_in_children_using_the_AL851_and_ALHR88_protocols:_a_report_from_the_Kyushu_Yamaguchi_Children's_Cancer_Study_Group_in_Japan_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0098-1532&amp;date=1996&amp;volume=26&amp;issue=1&amp;spage=10 DB - PRIME DP - Unbound Medicine ER -